Patent · US Active

Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions

US11826321B2 · kind B2 · utility

1Cited by

69References

7Claims

0Family size

Assignee

TONIX PHARMA LIMITED · BM

Inventors

Herbert Harris · Yeadon, US
Seth Lederman · New York, US

Key dates

Filing date	Dec 11, 2018
Grant date	Nov 28, 2023
Priority date	—
Expiry date	Dec 11, 2038

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K9/145
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Compositions comprising cyclobenzaprine, and methods for the treatment or prevention of agitation, psychosis and/or cognitive decline and associated symptoms thereof in dementia and other neurodegenerative conditions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.